Opinion|Videos|May 29, 2024
Overcoming Barriers to Better Patient Outcomes in PAH
Author(s)Ronald Oudiz, MD, FACP, FACC, FCCP
Ronald Oudiz, MD, FACP, FACC, FCCP, discusses the challenges and limitations associated with the adoption of new treatments and the impact of emerging therapies on patient outcomes, quality of life, and disease management in the long term.
Episodes in this series
Video content above is prompted by the following questions:
- What are the potential challenges or limitations associated with the adoption of new treatments, such as cost, access, or safety concerns?
- How might the evolving treatment landscape for PAH impact patient outcomes, quality of life, and disease management in the long term?
Related to this article
HYPERION trial data shows a 76% reduction in clinical worsening events among adults recently diagnosed with PAH.
Trending on AJMC
1
Health System Pharmacies Keep Patients on GLP-1 Therapy
2
Peptide Regulation Debate Intensifies After FDA Advisory Panel's Controversial Vote
3
Melatonin Use Linked to Small REM Sleep Reduction in Children
4
Opposing Sides of 340B Debate Converge on Data Clearinghouse, Patient Definition
5